[144] SOPHiA GENETICS SA SEC Filing

Rhea-AI Filing Summary

SOPHiA GENETICS SA (SOPH) filed a Form 144 disclosing a proposed sale of 83,558 common shares through Morgan Stanley Smith Barney with an aggregate market value of $345,094.54 and an approximate sale date of 09/29/2025. The filing shows acquisition details: 42,729 shares as founders' shares acquired 03/18/2011 and 40,829 shares from restricted stock units dated 10/02/2025. The filer also reported multiple recent Rule 10b5-1 sales and an individual sale totaling 40,829 shares on 08/19/2025 with gross proceeds of $142,493.21. The notice includes the required representation regarding absence of undisclosed material information.

Positive

• Compliance disclosure: The filer provided required Form 144 details including acquisition dates, nature of acquisitions, and planned broker execution via Morgan Stanley Smith Barney
• Use of 10b5-1 plans: Multiple reported 10b5-1 sales indicate trading under pre-established plans, which can reduce concerns about opportunistic insider trading

Negative

• Insider selling: Proposed sale of 83,558 shares valued at $345,094.54 and recent sales (including 40,829 shares on 08/19/2025) represent insider liquidity events that some investors may view negatively
• Concentration timing: Multiple sales concentrated in recent months could raise questions about continued insider selling activity

Insights

Securities Analyst

TL;DR: Insider intends to sell 83,558 shares (~$345k), following several recent 10b5-1 sales; size appears modest relative to outstanding shares.

The filing discloses a scheduled sale via Morgan Stanley Smith Barney and documents prior 10b5-1 and direct sales executed between July and September 2025. Total proposed sale value is $345,094.54 against 67,579,560 shares outstanding, indicating the sale represents a small fraction of the company's float. The disclosure satisfies Rule 144 reporting requirements and provides acquisition dates and nature (founders' shares and RSUs), which helps confirm transferability and holding periods.

Corporate Governance Expert

TL;DR: Disclosure appears compliant; multiple 10b5-1 transactions suggest pre-arranged trading plans rather than opportunistic selling.

The form includes the required attestation about no undisclosed material information and cites dates of acquisitions and payments for the securities to be sold. The presence of several 10b5-1 sales in the recent months indicates reliance on pre-established plans. From a governance perspective, timely Form 144 filings and explicit acquisition details support transparency, although continued insider selling may prompt investor questions about insider liquidity needs.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	83558	345094.54	67579560	09/29/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/18/2011	Founders Shares	Issuer			42729	03/18/2011	N/A
Common	10/02/2025	Restricted Stock Units	Issuer			40829	10/02/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for JURGI CAMBLONG La Piece 12 ch-1180 Rolle V8 00000	Common	09/26/2025	40971	166100.53
10b5-1 Sales for JURGI CAMBLONG La Piece 12 ch-1180 Rolle V8 00000	Common	09/23/2025	1300	5201.04
10b5-1 Sales for JURGI CAMBLONG La Piece 12 ch-1180 Rolle V8 00000	Common	09/19/2025	4486	14547.65
10b5-1 Sales for JURGI CAMBLONG La Piece 12 ch-1180 Rolle V8 00000	Common	08/19/2025	4487	15380.99
JURGI CAMBLONG La Piece 12 ch-1180 Rolle V8 00000	Common	08/19/2025	40829	142493.21
10b5-1 Sales for JURGI CAMBLONG La Piece 12 ch-1180 Rolle V8 00000	Common	07/23/2025	769	2711.19
10b5-1 Sales for JURGI CAMBLONG La Piece 12 ch-1180 Rolle V8 00000	Common	07/22/2025	2622	9397.25
10b5-1 Sales for JURGI CAMBLONG La Piece 12 ch-1180 Rolle V8 00000	Common	07/21/2025	1864	6618.50
10b5-1 Sales for JURGI CAMBLONG La Piece 12 ch-1180 Rolle V8 00000	Common	07/08/2025	15102	50390.84
10b5-1 Sales for JURGI CAMBLONG La Piece 12 ch-1180 Rolle V8 00000	Common	07/07/2025	9600	28887.36
10b5-1 Sales for JURGI CAMBLONG La Piece 12 ch-1180 Rolle V8 00000	Common	07/03/2025	2666	7946.28

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does SOPH Form 144 disclose about the proposed sale?

The Form 144 discloses a proposed sale of 83,558 common shares via Morgan Stanley Smith Barney with an aggregate market value of $345,094.54, approximately dated 09/29/2025.

How were the shares being sold acquired according to the filing?

The filing lists 42,729 founders' shares acquired on 03/18/2011 and 40,829 restricted stock units dated 10/02/2025.

Has the filer sold shares recently?

Yes. The filing reports multiple recent 10b5-1 sales between July and September 2025, including a sale of 40,829 shares on 08/19/2025 for $142,493.21.

What broker is handling the proposed sale?

The broker named in the filing is Morgan Stanley Smith Barney LLC located at 1 New York Plaza, 8th Floor, New York, NY 10004.

Does the Form 144 confirm there is no undisclosed material information?

Yes. By signing, the person for whose account the securities are to be sold represents they do not know any undisclosed material adverse information about the issuer.